{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:43:21Z","timestamp":1787507001330,"version":"build-2736575974"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Manipal Academy of Higher Education, Manipal"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diagn Pathol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Muscle-invasive bladder carcinomas (MIBCs) exhibit significant heterogeneity, with diverse histopathological features associated with varied prognosis and therapeutic response. Although genomic profiling studies have identified several molecular subtypes of MIBC, two basic molecular subtypes are identified - luminal and basal, differing in biological behaviour and response to treatment. As molecular subtyping is complex, surrogate immunohistochemical (IHC) markers have been used to determine the molecular subtypes with good correlation to genomic profiling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analysed the clinicopathological features of 66 cases of MIBCs received over a 5-year study period. IHC expression was determined using GATA3 and CK5\/6 to classify MIBC into luminal, basal and double-negative subtypes. The association between clinicopathologic variables and molecular subtypes were analysed using Chi-square test.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The mean age at diagnosis of MIBC was 65.91 years with a male predominance. Based on IHC expression of GATA3 and CK5\/6, MIBCs were classified into luminal, basal and double negative subtypes in 62.1%, 30.3% and 7.6% respectively. The luminal subtype occurred at an older age and showed predominantly conventional urothelial carcinoma with papillary morphology. Basal subtype occurred at earlier age, showed greater association with smoking and was more commonly associated with urothelial carcinoma with non -papillary morphology and exhibiting divergent differentiation as well as pure squamous cell carcinoma on histopathological examination. The double-negative subtype was found exclusively in males and exhibited a non-papillary morphology. Notably, all diagnosed neuroendocrine carcinomas were classified as double-negative type. While there was no statistically significant difference in tumour stage in cystectomy specimens between the molecular subtypes, lympho-vascular invasion and lymph node metastasis was more commonly associated with the basal type (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05) There was no significant difference in recurrence rates, metastasis and death between luminal and basal subtypes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>A simple two-antibody panel using GATA3 and CK5\/6 could help in classifying MIBC into basic molecular subtypes of MIBC with distinctive histopathological features that can provide insights into the corresponding molecular subtype. Greater association of lymphovascular invasion and lymph nodal involvement in cystectomy specimens in basal type and distant metastasis in the double-negative subtype suggests a more aggressive clinical behaviour of these, necessitating more intensive treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13000-025-01603-8","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T04:46:22Z","timestamp":1737693982000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Clinicopathological study and molecular subtyping of muscle-invasive bladder cancer (MIBC) using dual immunohistochemical (IHC) markers"],"prefix":"10.1186","volume":"20","author":[{"given":"R.","family":"Vaithegi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanthilatha","family":"Pai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuradha","family":"Calicut Kini Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vidya","family":"Monappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swathi","family":"Prabhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nischitha","family":"Suvarna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,24]]},"reference":[{"key":"1603_CR1","unstructured":"WHO Classification of Tumours Editorial Board. Urinary and male genital tumours. Lyon (France): International Agency for Research on Cancer; 2022 [cited 2024 09 30]. (WHO classification of tumours series, 5th ed.; vol. 8). Available from: https:\/\/tumourclassification.iarc.who.int\/chapters\/36"},{"issue":"3","key":"1603_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"1603_CR3","doi-asserted-by":"publisher","first-page":"151397","DOI":"10.1016\/j.anndiagpath.2019.08.001","volume":"43","author":"H Jangir","year":"2019","unstructured":"Jangir H, Nambirajan A, Seth A, Sahoo RK, Dinda AK, Nayak B, et al. Prognostic Stratification of Muscle Invasive Urothelial Carcinomas Using Limited Immunohistochemical Panel of Gata3 and cytokeratins 5\/6, 14 and 20. Ann Diagn Pathol. 2019;43:151397\u2013404.","journal-title":"Ann Diagn Pathol"},{"issue":"1","key":"1603_CR4","doi-asserted-by":"publisher","first-page":"9743","DOI":"10.1038\/s41598-020-66747-7","volume":"10","author":"CC Guo","year":"2020","unstructured":"Guo CC, Bondaruk J, Yao H, Wang Z, Zhang L, Lee S, et al. Assessment of Luminal and basal phenotypes in bladder Cancer. Sci Rep. 2020;10(1):9743.","journal-title":"Sci Rep"},{"key":"1603_CR5","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ebiom.2016.08.036","volume":"12","author":"V Dadhania","year":"2016","unstructured":"Dadhania V, Zhang M, Zhang L, Bondaruk J, Majewski T, Siefker-Radtke A, et al. Meta-analysis of the luminal and basal subtypes of bladder Cancer and the identification of signature immunohistochemical markers for clinical use. EBioMedicine. 2016;12:105\u201317.","journal-title":"EBioMedicine"},{"issue":"1","key":"1603_CR6","doi-asserted-by":"publisher","first-page":"21186","DOI":"10.1038\/s41598-021-00628-5","volume":"11","author":"T Bejrananda","year":"2021","unstructured":"Bejrananda T, Kanjanapradit K, Saetang J, Sangkhathat S. Impact of immunohistochemistry-based subtyping of GATA3, CK20, CK5\/6, and CK14 expression on survival after radical cystectomy for muscle-invasive bladder cancer. Sci Rep. 2021;11(1):21186.","journal-title":"Sci Rep"},{"issue":"4","key":"1603_CR7","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","volume":"77","author":"A Kamoun","year":"2020","unstructured":"Kamoun A, De Reyni\u00e8s A, Allory Y, Sj\u00f6dahl G, Robertson AG, Seiler R, et al. A Consensus Molecular classification of muscle-invasive bladder Cancer. Eur Urol. 2020;77(4):420\u201333.","journal-title":"Eur Urol"},{"key":"1603_CR8","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3389\/fonc.2020.00102","volume":"10","author":"S Zhu","year":"2020","unstructured":"Zhu S, Yu W, Yang X, Wu C, Cheng F. Traditional classification and novel subtyping systems for bladder cancer. Front Oncol. 2020;10:102.","journal-title":"Front Oncol"},{"issue":"8","key":"1603_CR9","doi-asserted-by":"publisher","first-page":"e0221785","DOI":"10.1371\/journal.pone.0221785","volume":"14","author":"CC Wang","year":"2019","unstructured":"Wang CC, Tsai YC, Jeng YM. Biological significance of GATA3, cytokeratin 20, cytokeratin 5\/6 and p53 expression in muscle-invasive bladder cancer. PLoS ONE. 2019;14(8):e0221785.","journal-title":"PLoS ONE"},{"issue":"1","key":"1603_CR10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13000-023-01295-y","volume":"18","author":"DS Helal","year":"2023","unstructured":"Helal DS, Darwish SA, Awad RA, Ali DA, El-Guindy DM. Immunohistochemical based molecular subtypes of muscle-invasive bladder cancer: association with HER2 and EGFR alterations, neoadjuvant chemotherapy response and survival. Diagn Pathol. 2023;18(1):11.","journal-title":"Diagn Pathol"},{"issue":"11","key":"1603_CR11","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1136\/jclinpath-2021-207573","volume":"75","author":"E Olkhov-Mitsel","year":"2021","unstructured":"Olkhov-Mitsel E, Hodgson A, Liu SK, Vesprini D, Xu B, Downes MR. Three-antibody classifier for muscle invasive urothelial carcinoma and its correlation with p53 expression. J Clin Pathol. 2021;75(11):766\u201371.","journal-title":"J Clin Pathol"},{"issue":"8","key":"1603_CR12","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s11547-022-01513-5","volume":"127","author":"M Bicchetti","year":"2022","unstructured":"Bicchetti M, Simone G, Giannarini G, Girometti R, Briganti A, Brunocilla E, et al. A novel pathway to detect muscle-invasive bladder cancer based on integrated clinical features and VI-RADS score on MRI: results of a prospective multicenter study. Radiol Med. 2022;127(8):881\u201390.","journal-title":"Radiol Med"},{"issue":"6","key":"1603_CR13","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.euf.2023.04.003","volume":"9","author":"JWF Catto","year":"2023","unstructured":"Catto JWF, Rogers Z, Downing A, Mason SJ, Jubber I, Bottomley S, et al. Lifestyle factors in patients with bladder cancer: a contemporary picture of tobacco smoking, electronic cigarette use, body mass index, and levels of physical activity. Eur Urol Focus. 2023;9(6):974\u201382.","journal-title":"Eur Urol Focus"},{"issue":"2","key":"1603_CR14","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/S0302-2838(01)00035-5","volume":"41","author":"E Satoh","year":"2002","unstructured":"Satoh E, Miyao N, Tachiki H, Fujisawa Y. Prediction of muscle invasion of bladder cancer by cystoscopy. Eur Urol. 2002;41(2):178\u201381.","journal-title":"Eur Urol"},{"issue":"7","key":"1603_CR15","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1002\/1097-0142(19901001)66:7<1630::AID-CNCR2820660730>3.0.CO;2-7","volume":"66","author":"WT Stephenson","year":"1990","unstructured":"Stephenson WT, Holmes FF, Noble MJ, Gerald KB. Analysis of bladder carcinoma by subsite. Cystoscopic location may have prognostic value. Cancer. 1990;66(7):1630\u20135.","journal-title":"Cancer"},{"issue":"6","key":"1603_CR16","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1080\/15321819.2021.1937212","volume":"42","author":"MM Serag Eldien","year":"2021","unstructured":"Serag Eldien MM, Abdou AG, Elghrabawy GRA, Alhanafy AM, Mahmoud SF. Stratification of urothelial bladder carcinoma depending on immunohistochemical expression of GATA3 and CK5\/6. J Immunoass Immunochem. 2021;42(6):662\u201378.","journal-title":"J Immunoass Immunochem"},{"issue":"9","key":"1603_CR17","first-page":"394","volume":"17","author":"NK Naga","year":"2023","unstructured":"Naga NK, Mina SN, El-Saka AM, El-Shorbagy SH, Amer AI. Immunohistochemical expression of GATA3, CK5\/6 and snail-1 in intrinsic subtypes of bladder carcinoma. Onkol Radioter. 2023;17(9):394\u2013400.","journal-title":"Onkol Radioter"},{"key":"1603_CR18","doi-asserted-by":"publisher","first-page":"875142","DOI":"10.3389\/fmed.2022.875142","volume":"9","author":"FJ Koll","year":"2022","unstructured":"Koll FJ, Schwarz A, K\u00f6llermann J, Banek S, Kluth L, Wittler C, et al. CK5\/6 and GATA3 defined phenotypes of muscle-invasive bladder Cancer: impact in Adjuvant Chemotherapy and Molecular Subtyping of negative cases. Front Med. 2022;9:875142.","journal-title":"Front Med"},{"issue":"6","key":"1603_CR19","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s10552-017-0885-z","volume":"28","author":"X Sun","year":"2017","unstructured":"Sun X, Hoadley KA, Kim WY, Furberg H, Olshan AF, Troester MA. Age at diagnosis, obesity, smoking, and molecular subtypes in muscle-invasive bladder cancer. Cancer Causes Control. 2017;28(6):539\u201344.","journal-title":"Cancer Causes Control"},{"key":"1603_CR20","doi-asserted-by":"publisher","first-page":"986598","DOI":"10.3389\/fimmu.2023.986598","volume":"14","author":"R Ben\u00edtez","year":"2023","unstructured":"Ben\u00edtez R, Yu K, Sirota M, Malats N, Pineda S. Characterization of the tumor-infiltrating immune repertoire in muscle invasive bladder cancer. Front Immunol. 2023;14:986598.","journal-title":"Front Immunol"},{"issue":"7","key":"1603_CR21","doi-asserted-by":"publisher","first-page":"6610","DOI":"10.3390\/ijms24076610","volume":"24","author":"F Sanguedolce","year":"2023","unstructured":"Sanguedolce F, Falagario UG, Zanelli M, Palicelli A, Zizzo M, Ascani S, et al. Clinicopathological Features and Survival Analysis in Molecular subtypes of muscle-invasive bladder Cancer. Int J Mol Sci. 2023;24(7):6610.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1603_CR22","first-page":"13","volume":"9","author":"H Mahmood","year":"2018","unstructured":"Mahmood H, Fatima H, Faheem M. Management of small cell neuroendocrine carcinoma of urinary bladder, a Case Series from Northern Pakistan. Cancer Ther Oncol Int J. 2018;9(1):13\u20136.","journal-title":"Cancer Ther Oncol Int J"},{"issue":"7","key":"1603_CR23","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1097\/PAI.0000000000000221","volume":"24","author":"L Verduin","year":"2016","unstructured":"Verduin L, Mentrikoski MJ, Heitz CT, Wick MR. The utility of GATA3 in the diagnosis of urothelial carcinoma with variant morphologic patterns. Appl Immunohistochem Mol Morphol. 2016;24(7):509\u201313.","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"5","key":"1603_CR24","first-page":"461","volume":"4","author":"Y Li","year":"2014","unstructured":"Li Y, Ishiguro H, Kawahara T, Miyamoto Y, Izumi K, Miyamoto H. GATA3 in the urinary bladder: suppression of neoplastic transformation and down-regulation by androgens. Am J Cancer Res. 2014;4(5):461\u201373.","journal-title":"Am J Cancer Res"}],"container-title":["Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-025-01603-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13000-025-01603-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-025-01603-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T04:46:28Z","timestamp":1737693988000},"score":1,"resource":{"primary":{"URL":"https:\/\/diagnosticpathology.biomedcentral.com\/articles\/10.1186\/s13000-025-01603-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,24]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1603"],"URL":"https:\/\/doi.org\/10.1186\/s13000-025-01603-8","relation":{},"ISSN":["1746-1596"],"issn-type":[{"value":"1746-1596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,24]]},"assertion":[{"value":"1 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Institutional Ethics Committee of Katurba Medical College, Manipal (IEC2: 449\/2022). Informed consent was waived off due to the retrospective nature of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10"}}